Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 16
1966 19
1967 14
1968 17
1969 23
1970 16
1971 15
1972 11
1973 23
1974 21
1975 12
1976 15
1977 17
1978 29
1979 26
1980 22
1981 19
1982 35
1983 30
1984 26
1985 36
1986 21
1987 50
1988 27
1989 48
1990 27
1991 26
1992 32
1993 27
1994 33
1995 32
1996 36
1997 30
1998 35
1999 37
2000 41
2001 26
2002 35
2003 34
2004 57
2005 37
2006 50
2007 46
2008 45
2009 47
2010 52
2011 60
2012 67
2013 58
2014 70
2015 68
2016 73
2017 44
2018 49
2019 57
2020 32
2021 30
2022 10
2023 8
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

1,839 results

Results by year

Filters applied: . Clear all
Page 1
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Mateos MV, et al. Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10. Lancet. 2020. PMID: 31836199 Clinical Trial.
Melphalan-Induced Atrial Fibrillation.
Shah AJ, Kobrossi S, Desai A. Shah AJ, et al. Am J Ther. 2018 Sep/Oct;25(5):e571-e572. doi: 10.1097/MJT.0000000000000651. Am J Ther. 2018. PMID: 28816723 No abstract available.
Current treatment for multiple myeloma.
Avigan D, Rosenblatt J. Avigan D, et al. N Engl J Med. 2014 Sep 4;371(10):961-2. doi: 10.1056/NEJMe1407442. N Engl J Med. 2014. PMID: 25184869 No abstract available.
Blue toe syndrome--reply.
Sarici A, Kizilkilic O, Celkan T. Sarici A, et al. JAMA Ophthalmol. 2014 May;132(5):654-5. doi: 10.1001/jamaophthalmol.2013.8252. JAMA Ophthalmol. 2014. PMID: 24810698 No abstract available.
The mutagenic impact of melphalan in multiple myeloma.
Maura F, Weinhold N, Diamond B, Kazandjian D, Rasche L, Morgan G, Landgren O. Maura F, et al. Leukemia. 2021 Aug;35(8):2145-2150. doi: 10.1038/s41375-021-01293-3. Epub 2021 May 19. Leukemia. 2021. PMID: 34012133 Review.
Reply.
Francis JH, Abramson DH, Gaillard MC, Marr BP, Beck-Popovic M, Munier FL. Francis JH, et al. Ophthalmology. 2016 Feb;123(2):e10-e11. doi: 10.1016/j.ophtha.2015.07.015. Ophthalmology. 2016. PMID: 26802712 No abstract available.
Encephalopathy following melphalan administration.
Dubey D, Freeman M, Neeley OJ, Carter G. Dubey D, et al. J Chemother. 2017 Feb;29(1):45-48. doi: 10.1179/1973947814Y.0000000231. Epub 2016 Apr 22. J Chemother. 2017. PMID: 25579321
1,839 results